Flagellin mutant of Salmonella typhimurium VNP20009 producing recombinant mouse PD-1 preserves the growth kinetics and mobility of the parental strain

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Flagellin mutant of Salmonella typhimurium VNP20009 producing recombinant mouse PD-1 preserves the growth kinetics and mobility of the parental strain

Joint Event on 28th International Conference on Cancer Research and Anticancer Therapies & International Conference on Oncogenesis & Oncologic Emergency Medicine & 3rd International Conference on Tumor & Cancer Immunology and I

September 17-18, 2018 | San Diego, USA

Edyta Zyla, Mateusz Wawro and Joanna Bereta

Jagiellonian University, Poland

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

The interaction of PD-L1 with T cell PD-1 receptor leads to the inactivation and death of T cells resulting in immunosuppression and undisturbed tumor development. We engineered Salmonella strain to deliver soluble PD-1 into tumor tissue. In principle, soluble PD-1 will compete with the PD-1 receptor on the T cell surface for binding to the PD-L1 ligand present on the surface of tumor cells and thus prevent T cell inactivation. The main goal of this work was to modify Salmonella therapeutic strain so it will be capable of efficiently secreting soluble PD-1 through the flagellar system. The flagellar system functions as a bacterial mobility motor but also serves as a secretory system for the extracellular elements of the flagellum. Special secretion signals direct certain proteins for flagellar channel-mediated secretion. To use the flagellar system for the secretion of recombinant proteins bacteria should be deprived of flagellin synthesis. To achieve this, we removed the fliC gene coding for flagellin monomer from the VNP20009 chromosome by homologous recombination and transformed the new strain with a plasmid coding for soluble PD-1 equipped with a suitable secretion signal. At present we are testing various secretion signals for optimal synthesis and secretion of PD-1 via the flagellar system. Interestingly, the characterization of the ╬?fliC strain showed similarities characteristics to the parental one in terms of viability and growth kinetics. What is more, the mobility of the modified bacteria and the wild-type VNP20009 did not differ. However, the exposure of RAW264.7 cells to both Salmonella strains revealed that ╬?fliC bacteria are less infective when compared to the parental strain. Nonetheless, in this case, the decreased cell infectivity might be beneficial as it will allow secreting PD-1 to the extracellular environment, where it may fulfill its anti-immunosuppressive task.

Biography :

Edyta Zyla has been started her PhD studies at Jagiellonian University in Kraków. From the very first beggining of Bachelor studies she was gripped by Salmonella using in anticancer immunotherapy. She was chairing student project and currently she is beneficiary of project financed by Biophysics, Biochemistry and Biotechnology Department UJ. To expand her horizons she has started working in Protein Crystallography Laboratory.



Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

arrow_upward arrow_upward